RVMD Q1 2023 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$20B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M-7.4% YoY

Gross Profit

$7M100.0% margin

Operating Income

-$75M-1071.5% margin

Net Income

-$68M-970.9% margin

EPS (Diluted)

$-0.62

QoQ Revenue Growth

-54.2%

Cash Flow

Operating Cash Flow

-$62M

Free Cash Flow

-$64M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$121M

Stockholders' Equity

$952M

Cash & Equivalents

$427M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$8M	-7.4%
Gross Profit	$7M	$8M	-7.4%
Operating Income	-$75M	-$58M	-29.7%
Net Income	-$68M	-$58M	-18.1%

Revenue Segments

Collaboration Revenue Member

$7M100%